collection
MENU ▼
Read by QxMD icon Read
search

Multiple Sclerosis

shared collection
395 papers 25 to 100 followers
By Alexandros Tsichlakis Medical representative
https://www.readbyqxmd.com/read/27882532/alemtuzumab-use-in-clinical-practice-recommendations-from-european-multiple-sclerosis-experts
#1
Thomas Berger, Irina Elovaara, Sten Fredrikson, Chris McGuigan, Lucia Moiola, Kjell-Morten Myhr, Celia Oreja-Guevara, Igor Stoliarov, Uwe K Zettl
Alemtuzumab (Lemtrada™) is a humanized monoclonal antibody approved in more than 50 countries. Within the European Union, alemtuzumab is indicated for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features; in the USA, the indication states that alemtuzumab should generally be reserved for the treatment of patients with relapsing forms of multiple sclerosis who have had an inadequate response to two or more disease-modifying therapies (DMTs)...
November 23, 2016: CNS Drugs
https://www.readbyqxmd.com/read/27813441/primary-progressive-multiple-sclerosis-current-therapeutic-strategies-and-future-perspectives
#2
Alberto Gajofatto, Marco Turatti, Maria Donata Benedetti
Multiple sclerosis (MS) is a chronic inflammatory condition of the central nervous system with heterogeneous features. Primary progressive (PP) MS is a rare disease subtype characterized by continuous disability worsening from onset. No disease-modifying therapy is currently approved for PP MS due to the negative or inconsistent results of clinical trials conducted on a wide range of interventions, which are reviewed in the present paper. Areas covered: The features and results of randomized trials of disease-modifying treatments for PP MS are discussed, including immunosuppressants, immunomodulators, monoclonal antibodies, and putative neuroprotective agents...
November 4, 2016: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/27006700/fingolimod-in-the-treatment-of-relapsing-remitting-multiple-sclerosis-long-term-experience-and-an-update-on-the-clinical-evidence
#3
REVIEW
Bhupendra O Khatri
Since the approval in 2010 of fingolimod 0.5 mg (Gilenya; Novartis Pharma AG, Basel, Switzerland) in the USA as an oral therapy for relapsing forms of multiple sclerosis, long-term clinical experience with this therapy has been increasing. This review provides a summary of the cumulative dataset from clinical trials and their extensions, plus postmarketing studies that contribute to characterizing the efficacy and safety profile of fingolimod in patients with relapsing forms of multiple sclerosis. Data from the controlled, phase III, pivotal studies [FREEDOMS (FTY720 Research Evaluating Effects of Daily Oral therapy in Multiple Sclerosis), FREEDOMS II and TRANSFORMS (Trial Assessing Injectable Interferon versus FTY720 Oral in Relapsing-Remitting Multiple Sclerosis)] in relapsing-remitting multiple sclerosis have shown that fingolimod has a robust effect on clinical and magnetic resonance imaging outcomes...
March 2016: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/27502119/study-design-of-pangaea-2-0-a-non-interventional-study-on-rrms-patients-to-be-switched-to-fingolimod
#4
Tjalf Ziemssen, Raimar Kern, Christian Cornelissen
BACKGROUND: The therapeutic options for patients with Multiple Sclerosis (MS) have steadily increased due to the approval of new substances that now supplement traditional first-line agents, demanding a paradigm shift in the assessment of disease activity and treatment response in clinical routine. Here, we report the study design of PANGAEA 2.0 (Post-Authorization Non-interventional GermAn treatment benefit study of GilEnyA in MS patients), a non-interventional study in patients with relapsing-remitting MS (RRMS) identify patients with disease activity and monitor their disease course after treatment switch to fingolimod (Gilenya®), an oral medication approved for patients with highly active RRMS...
August 8, 2016: BMC Neurology
https://www.readbyqxmd.com/read/27663260/to-fingolimod-and-beyond-the-rich-pipeline-of-drug-candidates-that-target-s1p-signaling
#5
REVIEW
Wee Siong Chew, Wei Wang, Deron R Herr
Sphingosine 1-phosphate (S1P) is an extracellular lipid signaling molecule that acts as a selective, high-affinity ligand for a family of five G protein-coupled receptors. This signaling system was first identified twenty years ago, and has since been shown to regulate a diverse range of physiological processes and disease states, such as cardiovascular development, immune function, hypoxic responses, and cancer. The therapeutic potential of targeting this system took center stage when it was demonstrated that the immune modulator, fingolimod (FTY720/Gilenya), exerts it lymphopenic effect by acting on S1P receptors, primarily on S1P receptor 1 (S1P1)...
November 2016: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/27624575/cardiac-safety-profile-of-first-dose-of-fingolimod-for-relapsing-remitting-multiple-sclerosis-in-real-world-settings-data-from-a-german-prospective-multi-center-observational-study
#6
Ralf A Linker, Guillaume Wendt
INTRODUCTION: Fingolimod was the first oral therapy approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). Due to its action on cardiac sphingosine 1-phosphate receptors, fingolimod is leading to a transient decrease in heart rate (HR) and the occurrence of rare and asymptomatic self-limited atrioventricular (AV) blocks. This German non-interventional clinical study aimed to assess the cardiac safety profile in RRMS patients during at least 6 h after the initial treatment or restart after interruption of fingolimod in real-world settings...
December 2016: Neurology and Therapy
https://www.readbyqxmd.com/read/27645342/cryptococcal-meningitis-after-fingolimod-discontinuation-in-a-patient-with-multiple-sclerosis
#7
Melanie D Ward, David E Jones, Myla D Goldman
Fingolimod (Gilenya, Novartis) is an oral sphingosine-1-phosphate analogue used in the treatment of relapsing multiple sclerosis (MS). Fingolimod treatment is associated with relative lymphopenia and was associated with an increased risk of herpes infection in clinical trials. In the post-marketing setting, fingolimod has been associated with several cases of cryptococcal meningitis, recently prompting an update to its prescribing information. To date, all cases have been associated with active treatment with fingolimod...
September 2016: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/27658434/-fingolimod-effectiveness-and-safety-in-routine-clinical-practice-an-observational-retrospective-multi-centre-study-in-navarra-gipuzkoa-and-la-rioja
#8
T Ayuso, M E Marzo-Sola, T Castillo-Trivino, G Soriano, M A Otano, M A Lopez, I M Croitoru, J Olascoaga
AIM: To evaluate the effectiveness and safety of fingolimod in clinical practice in Navarra, Gipuzkoa and La Rioja regions. PATIENTS AND METHODS: We conducted a retrospective multi-centre study with recurrent multiple sclerosis patients treated with fingolimod, following the product data sheet. The following data were evaluated: annualised relapse rate (ARR), percentage of patients free from relapses, disability using the Expanded Disability Status Scale (EDSS) and the percentage of patients without gadolinium-enhancing lesions...
September 5, 2016: Revista de Neurologia
https://www.readbyqxmd.com/read/27671228/neuroprotective-effects-of-fingolimod-in-mouse-models-of-parkinson-s-disease
#9
Peng Zhao, Xiaoxia Yang, Liu Yang, Minshu Li, Kristofer Wood, Qiang Liu, Xiaodong Zhu
Parkinson's disease (PD) is characterized by a progressive loss of dopaminergic neurons with limited treatment options. Emerging evidence shows that FTY720 protects against neural injury via modulation of the S1P1 receptor. However, it remains unclear whether FTY720 could influence neurodegeneration in PD. Therefore, the present study was designed to determine the impact of fingolimod (FTY720), a sphingosine-1-phosphate receptor (S1PR) agonist, on 2 mouse models of PD. We found that FTY720 significantly reduced the deficit of motor function, diminished the loss of tyrosine hydroxylase-positive neurons in the substantia nigra, and attenuated the decrease of striatal dopamine and metabolite levels in mice receiving 6-hydroxydopamine (6-OHDA) or rotenone to simulate PD...
September 26, 2016: FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology
https://www.readbyqxmd.com/read/27684943/the-efficacy-of-natalizumab-versus-fingolimod-for-patients-with-relapsing-remitting-multiple-sclerosis-a-systematic-review-indirect-evidence-from-randomized-placebo-controlled-trials-and-meta-analysis-of-observational-head-to-head-trials
#10
Georgios Tsivgoulis, Aristeidis H Katsanos, Dimitris Mavridis, Nikolaos Grigoriadis, Efthymios Dardiotis, Ioannis Heliopoulos, Panagiotis Papathanasopoulos, Theodoros Karapanayiotides, Constantinos Kilidireas, Georgios M Hadjigeorgiou, Konstantinos Voumvourakis
BACKGROUND: Although Fingolimod (FGD) and Natalizumab (NTZ) appear to be effective in relapsing-remitting multiple sclerosis (RRMS), they have never been directly compared in a randomized clinical trial (RCT). METHODS AND FINDINGS: We evaluated the comparative efficacy of FGD vs. NTZ using a meta-analytical approach. Data from placebo-controlled RCTs was used for indirect comparisons and observational data was utilized for head-to-head comparisons. We identified 3 RCTs (2498 patients) and 5 observational studies (2576 patients)...
2016: PloS One
https://www.readbyqxmd.com/read/27696299/treatment-related-progressive-multifocal-leukoencephalopathy-in-multiple-sclerosis-a-comprehensive-review-of-current-evidence-and-future-needs
#11
REVIEW
Emanuele D'Amico, Aurora Zanghì, Carmela Leone, Hayrettin Tumani, Francesco Patti
Progressive multifocal leukoencephalopathy (PML) is a rare opportunistic infection of the central nervous system caused by the John Cunningham virus (JCV) that has been associated with therapeutic immunosuppression in patients with multiple sclerosis (MS). So far, more than 600 cases of PML have been reported in association with natalizumab administration. There have also been confirmed cases of PML in individuals who received fingolimod and dimethyl fumarate without previous natalizumab treatment. The new licensed disease-modifying therapies for MS carry the risk of immunosuppressant and so of JCV reactivation...
December 2016: Drug Safety: An International Journal of Medical Toxicology and Drug Experience
https://www.readbyqxmd.com/read/25891589/siponimod-baf312-for-the-treatment-of-secondary-progressive-multiple-sclerosis-design-of-the-phase-3-expand-trial
#12
L Kappos, A Bar-Or, B Cree, R Fox, G Giovannoni, R Gold, P Vermersch, E Lam, H Pohlmann, E Wallström
BACKGROUND/OBJECTIVE: Siponimod (BAF312), a next generation selective sphingosine 1-phosphate (S1P)-1 and -5 receptor modulator administered once-daily orally reduces lymphocyte infiltration into the CNS and may have direct CNS effects. Experimental studies indicate that siponimod readily crosses the blood-brain-barrier and may modulate neurobiological processes via S1P1 and S1P5 receptors on astrocytes and oligodendrocytes. In relapsing MS, S1P receptor modulation reduces accumulation of neurological impairment and slows progression of brain atrophy...
November 2014: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/26239599/sphingosine-1-phosphate-receptor-modulators-in-multiple-sclerosis
#13
REVIEW
Adnan M Subei, Jeffrey A Cohen
Sphingosine 1-phosphate (S1P) receptor modulators possess a unique mechanism of action as disease-modifying therapy for multiple sclerosis (MS). Subtype 1 S1P receptors are expressed on the surfaces of lymphocytes and are important in regulating egression from lymph nodes. The S1P receptor modulators indirectly antagonize the receptor's function and sequester lymphocytes in lymph nodes. Fingolimod was the first S1P agent approved in the USA in 2010 for relapsing MS after two phase III trials (FREEDOMS and TRANSFORMS) demonstrated potent efficacy, and good safety and tolerability...
July 2015: CNS Drugs
https://www.readbyqxmd.com/read/27566665/siponimod-baf312-prevents-synaptic-neurodegeneration-in-experimental-multiple-sclerosis
#14
Antonietta Gentile, Alessandra Musella, Silvia Bullitta, Diego Fresegna, Francesca De Vito, Roberta Fantozzi, Eleonora Piras, Francesca Gargano, Giovanna Borsellino, Luca Battistini, Anna Schubart, Georgia Mandolesi, Diego Centonze
BACKGROUND: Data from multiple sclerosis (MS) and the MS rodent model, experimental autoimmune encephalomyelitis (EAE), highlighted an inflammation-dependent synaptopathy at the basis of the neurodegenerative damage causing irreversible disability in these disorders. This synaptopathy is characterized by an imbalance between glutamatergic and GABAergic transmission and has been proposed to be a potential therapeutic target. Siponimod (BAF312), a selective sphingosine 1-phosphate1,5 receptor modulator, is currently under investigation in a clinical trial in secondary progressive MS patients...
2016: Journal of Neuroinflammation
https://www.readbyqxmd.com/read/27604618/vaccines-and-multiple-sclerosis-a-systematic-review
#15
Mia Topsøe Mailand, Jette Lautrup Frederiksen
Vaccinations are often the most effective tool against some disease known to mankind. This study offers a literature review on the role of vaccines regarding the risk of developing multiple sclerosis (MS) and MS relapse. The method used in this study is a systematic literature review on the database PubMed. The study found no change in risk of developing multiple sclerosis (MS) after vaccination against hepatitis B virus, human papillomavirus, seasonal influenza, measles-mumps-rubella, variola, tetanus, Bacillus Calmette-Guérin (BCG), polio, or diphtheria...
September 7, 2016: Journal of Neurology
https://www.readbyqxmd.com/read/27612279/cancer-co-occurrence-patterns-in-parkinson-s-disease-and-multiple-sclerosis-do-they-mirror-immune-system-imbalances
#16
Vladeta Ajdacic-Gross, Stephanie Rodgers, Aleksandra Aleksandrowicz, Margot Mutsch, Nina Steinemann, Viktor von Wyl, Roland von Känel, Matthias Bopp
BACKGROUND: To examine the site-specific cancer mortality among deaths registered with Parkinson's disease (PD) and multiple sclerosis (MS). We focused on the patterns related to the most frequent cancers. METHODS: We analyzed Swiss mortality data over a 39-year period (1969-2007), using a statistical approach applicable to unique daabases, i.e. when no linkage with morbidity databases or disease registries is possible. It was based on a case-control design with bootstrapping to derive standardized mortality ratios (SMR)...
October 2016: Cancer Epidemiology
https://www.readbyqxmd.com/read/27552111/ocrelizumab-for-the-treatment-of-relapsing-remitting-multiple-sclerosis
#17
Til Menge, Divyanshu Dubey, Clemens Warnke, Hans-Peter Hartung, Olaf Stüve
INTRODUCTION: Despite recent advances in pharmacological management, multiple sclerosis (MS), an autoimmune disease of the central nervous system, remains a leading cause of disability. In relapsing-remitting (RR)MS, neurologists most commonly utilize immunomodulatory or immunosuppressive agents to benefit their patients. With the introduction of humanized monoclonal antibodies (mAbs) ablation of distinct immune populations has become possible. Depletion of B cells by anti-CD20 mAbs has repeatedly proven to be a very rapid and effective means to diminish disease activity in RRMS...
October 2016: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/27461166/safety-and-efficacy-of-daclizumab-in-relapsing-remitting-multiple-sclerosis-3-year-results-from-the-selected-open-label-extension-study
#18
Ralf Gold, Ernst-Wilhelm Radue, Gavin Giovannoni, Krzysztof Selmaj, Eva Havrdova, Dusan Stefoski, Till Sprenger, Xavier Montalban, Stanley Cohan, Kimberly Umans, Steven J Greenberg, Gulden Ozen, Jacob Elkins
BACKGROUND: Daclizumab is a humanized monoclonal antibody against CD25 that modulates interleukin 2 signaling. The SELECT TRILOGY of clinical studies (SELECT/SELECTION/SELECTED) evaluated the safety and efficacy of daclizumab in patients with relapsing-remitting multiple sclerosis (RRMS). We report the long-term safety and efficacy of daclizumab 150 mg subcutaneous every 4 weeks in patients with RRMS in the SELECTED open-label extension study. METHODS: An interim intent-to-treat analysis of all enrolled patients was performed in January 2014 for this ongoing study...
2016: BMC Neurology
https://www.readbyqxmd.com/read/27606353/nonfatal-pml-in-a-patient-with-multiple-sclerosis-treated-with-dimethyl-fumarate
#19
Moogeh Baharnoori, Jennifer Lyons, Akram Dastagir, Igor Koralnik, James M Stankiewicz
No abstract text is available yet for this article.
October 2016: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/27604188/the-real-world-patient-experience-of-fingolimod-and-dimethyl-fumarate-for-multiple-sclerosis
#20
Paul Wicks, Lawrence Rasouliyan, Bo Katic, Beenish Nafees, Emuella Flood, Rahul Sasané
BACKGROUND: Oral disease-modifying therapies offer equivalent or superior efficacy and greater convenience versus injectable options. OBJECTIVES: To compare patient-reported experiences of fingolimod and dimethyl fumarate. METHODS: Adult relapsing-remitting multiple sclerosis patients treated with fingolimod or dimethyl fumarate were recruited from an online patient community and completed an online survey about treatment side effects, discontinuation, and satisfaction...
2016: BMC Research Notes
label_collection
label_collection
3746
1
2
2016-09-11 10:20:05
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"